Boston Scientific Corporation

1606 articles about Boston Scientific Corporation

• Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies

  5/20/2023

  Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure Device.

• Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference

  5/15/2023

  Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.

• Boston Scientific Announces Results for First Quarter 2023

  4/26/2023

  Boston Scientific Corporation generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period.

• Boston Scientific Announces Conference Call Discussing First Quarter 2023 Results

  4/3/2023

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m. EDT.

• Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference

  2/13/2023

  Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Wednesday, March 1, 2023.

• BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

  2/1/2023

  Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational 1 basis and 7.1 percent on an organic 2 basis, all compared to the prior year period.

• Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results

  1/3/2023

  Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California.

• Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited

  12/11/2022

  Boston Scientific Corporation and Acotec Scientific Holdings Limited announced that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures.

• Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.

  11/29/2022

  Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.

• Boston Scientific Announces Upcoming November 2022 Conference Schedule

  11/1/2022

  On November 15, 2022, Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at the 2022 Stifel Healthcare Conference.

• Boston Scientific Announces Results for Third Quarter 2022

  10/26/2022

  Boston Scientific Corporation generated net sales of $3.170 billion during the third quarter of 2022, growing 8.1 percent on a reported basis, 13.7 percent on an operational1 basis and 11.5 percent on an organic2 basis, all compared to the prior year period.

• Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection System

  9/17/2022

  Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection System, which is designed to capture and remove embolic debris stemming from transcatheter aortic valve replacement before it can reach the brain and potentially cause a stroke.

• Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

  9/6/2022

  Boston Scientific Corporation has received U.S. Food and Drug Administration approval to expand the instructions for use labeling for the current-generation WATCHMAN FLX™ Left Atrial Appendage Closure Device to include a 45-day dual anti-platelet therapy option as an alternative to 45-day oral anticoagulation plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation.

• Boston Scientific Announces Upcoming Conference Schedule

  8/16/2022

  Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events.

• Boston Scientific Announces Acquisition of Obsidio, Inc.

  8/15/2022

  Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM ™ ) technology used for embolization of blood vessels in the peripheral vasculature.

• Boston Scientific Announces Results for Second Quarter 2022

  7/27/2022

  Boston Scientific Corporation generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and 6.6 percent on an organic2 basis, all compared to the prior year period.

• Boston Scientific Announces Conference Call Discussing Second Quarter 2022 Results

  6/29/2022

  Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT.

• Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd

  6/15/2022

  Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, ("M.I.Tech").

• Boston Scientific to Participate in Bank of America Global Healthcare Conference

  5/2/2022

  Boston Scientific Corporation will participate in Bank of America's Global Healthcare Conference on Thursday, May 12.

• Boston Scientific Announces Results For First Quarter 2022

  4/27/2022

  Boston Scientific Corporation generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period.